Navigating the Intersection of GLP-1 Medications and Sleep Apnea: What Patients Need to Know on October 22, 2026 Posted by
FDA Medical Device Center Faces Critical Rebuilding Phase After Mass Attrition on October 22, 2026 Posted by
Unlocking the Molecular Mystery: New Research Paves the Way for Safer Statins on October 22, 2026 Posted by
The Future of Healing: CRI’s 2026 Gala Spotlights the "Next is Now" Era of Immunotherapy on October 22, 2026 Posted by
The Hidden Killer on Our Highways: Confronting the Escalating Crisis of Drowsy Driving on October 22, 2026 Posted by
A New Frontier in Preventive Medicine: The Inaugural EU Screening Week and the Future of Respiratory Health on October 21, 2026 Posted by
Breakthrough in Prosthetic Innovation: Point Designs Unveils Merge MID for Mid-Phalanx Amputations, Redefining Independence on October 21, 2026 Posted by
Navigating the Intersection of GLP-1 Medications and Sleep Apnea: What Patients Need to Know on October 22, 2026 Posted by
FDA Medical Device Center Faces Critical Rebuilding Phase After Mass Attrition on October 22, 2026 Posted by
Unlocking the Molecular Mystery: New Research Paves the Way for Safer Statins on October 22, 2026 Posted by
The Future of Healing: CRI’s 2026 Gala Spotlights the "Next is Now" Era of Immunotherapy on October 22, 2026 Posted by
Posted in Medical Innovations New Frontier in Lung Cancer: Zidesamtinib Shows Unprecedented Efficacy in Frontline ROS1-Positive NSCLC Treatment on September 15, 2026
Posted in Medical Innovations Trial Disappointment: Sacituzumab Govitecan Fails to Boost Survival in Front-Line NSCLC on September 13, 2026
Posted in Medical Innovations Clinical Setback: Local Consolidative Therapy Fails to Enhance Outcomes in Metastatic NSCLC Patients on September 12, 2026
Posted in Medical Innovations New Hope for Advanced Lung Cancer: FDA Approves Zidesamtinib for Pre-Treated ROS1-Positive NSCLC on July 23, 2026
Posted in Respiratory Health Precision Oncology Milestone: GSK’s Jideytro (Zidesamtinib) Receives Landmark FDA Approval for ROS1-Positive NSCLC on July 22, 2026
Posted in Medical Innovations A New Horizon in Oncology: Bispecific Antibody Ivonescimab Sets a Higher Bar for Squamous NSCLC Treatment on June 1, 2026 rifanmuazin
Posted in Medical Innovations A New Era in Lung Cancer Care: Selpercatinib Establishes Standard for RET Fusion-Positive NSCLC on May 31, 2026 rifanmuazin
Posted in Medical Innovations A New Frontier in Lung Cancer: Sunvozertinib Challenges Chemotherapy in First-Line NSCLC Treatment on May 30, 2026 rifanmuazin
